Jäger D, Stockert E, Güre A O, Scanlan M J, Karbach J, Jäger E, Knuth A, Old L J, Chen Y T
Weill Medical College of Cornell University, New York, New York 10021, USA.
Cancer Res. 2001 Mar 1;61(5):2055-61.
Application of SEREX (serological analysis of recombinant tumor cDNA expression libraries) to different tumor types has led to the identification of several categories of human tumor antigens. In this study, the analysis of a breast cancer library with autologous patient serum led to the isolation of seven genes, designated NY-BR-1 through NY-BR-7. NY-BR-1, representing 6 of 14 clones isolated, showed tissue-restricted mRNA expression in breast and testis but not in 13 other normal tissues tested. Among tumor specimens, NY-BR-1 mRNA expression was found in 21 of 25 breast cancers but in only 2 of 82 nonmammary tumors. Structural analysis of NY-BR-1 cDNA and the corresponding genomic sequences in the recently released working draft of human genome indicated that NY-BR-1 is composed of 37 exons and has an open reading frame of 4.0-4.2 kb, encoding a peptide of Mr 150,000-160,000. A bipartite nuclear localization signal motif indicates a nuclear site for NY-BR-1, and the presence of a bZIP site (DNA-binding site followed by leucine zipper motif) suggests that NY-BR-1 is a transcription factor. Additional structural features include five tandem ankyrin repeats, implying a role for NY-BR-1 in protein-protein interactions. NY-BR-1 thus represents a breast tissue-specific putative transcription factor with autoimmunogenicity in breast cancer patients. In addition to NY-BR-1, a homologous gene, NY-BR-1.1, was identified in this study. NY-BR-1.1 shares 54% amino acid homology with NY-BR-1 and also shows tissue-restricted mRNA expression. However, unlike NY-BR-1, NY-BR-1.1 mRNA is expressed in brain, in addition to breast and testis. The exon structure of NY-BR-1.1 remains to be defined. Using human genome database, NY-BR-1 was localized to chromosome 10p11-p12, and NY-BR-1.1 was tentatively localized to chromosome 9.
将SEREX(重组肿瘤cDNA表达文库血清学分析)应用于不同肿瘤类型已导致鉴定出几类人类肿瘤抗原。在本研究中,用自体患者血清分析乳腺癌文库导致分离出7个基因,命名为NY-BR-1至NY-BR-7。NY-BR-1代表所分离的14个克隆中的6个,在乳腺和睾丸中显示出组织限制性mRNA表达,但在其他13种测试的正常组织中未显示。在肿瘤标本中,25例乳腺癌中有21例发现NY-BR-1 mRNA表达,但82例非乳腺肿瘤中只有2例表达。对NY-BR-1 cDNA和人类基因组最新发布的工作草图中的相应基因组序列进行结构分析表明,NY-BR-1由37个外显子组成,具有4.0 - 4.2 kb的开放阅读框,编码一个分子量为150,000 - 160,000的肽。一个双分型核定位信号基序表明NY-BR-1定位于细胞核,并且存在一个bZIP位点(DNA结合位点后接亮氨酸拉链基序)表明NY-BR-1是一种转录因子。其他结构特征包括五个串联锚蛋白重复序列,这意味着NY-BR-1在蛋白质 - 蛋白质相互作用中起作用。因此,NY-BR-1代表一种乳腺组织特异性的假定转录因子,在乳腺癌患者中具有自身免疫原性。除了NY-BR-1,本研究中还鉴定出一个同源基因NY-BR-1.1。NY-BR-1.1与NY-BR-1共享54%的氨基酸同源性,并且也显示出组织限制性mRNA表达。然而,与NY-BR-1不同,NY-BR-1.1 mRNA除了在乳腺和睾丸中表达外,还在脑中表达。NY-BR-1.1的外显子结构仍有待确定。利用人类基因组数据库,NY-BR-1定位于10号染色体p11 - p12,NY-BR-1.1初步定位于第9号染色体。